Oregon Public Employees Retirement Fund trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 6.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,335 shares of the company’s stock after selling 512 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Medpace were worth $1,153,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Raymond James & Associates boosted its stake in Medpace by 11.9% during the third quarter. Raymond James & Associates now owns 80,422 shares of the company’s stock worth $12,640,000 after buying an additional 8,562 shares during the period. Forte Capital LLC ADV boosted its stake in Medpace by 42.6% during the third quarter. Forte Capital LLC ADV now owns 2,680 shares of the company’s stock worth $421,000 after buying an additional 800 shares during the period. Hancock Whitney Corp boosted its stake in Medpace by 10.9% during the third quarter. Hancock Whitney Corp now owns 45,820 shares of the company’s stock worth $7,202,000 after buying an additional 4,494 shares during the period. Dupont Capital Management Corp boosted its stake in Medpace by 304.1% during the third quarter. Dupont Capital Management Corp now owns 7,516 shares of the company’s stock worth $1,181,000 after buying an additional 5,656 shares during the period. Finally, First National Bank of Omaha boosted its stake in Medpace by 85.6% during the second quarter. First National Bank of Omaha now owns 4,856 shares of the company’s stock worth $727,000 after buying an additional 2,240 shares during the period. 82.49% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Medpace
In related news, General Counsel Stephen P. Ewald sold 6,500 shares of Medpace stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $220.53, for a total value of $1,433,445.00. Following the completion of the sale, the general counsel now directly owns 14,854 shares in the company, valued at $3,275,752.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 20.60% of the stock is currently owned by corporate insiders.
Medpace Price Performance
Medpace (NASDAQ:MEDP – Get Rating) last released its quarterly earnings data on Monday, October 24th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.58. The firm had revenue of $383.74 million during the quarter, compared to the consensus estimate of $357.17 million. Medpace had a return on equity of 41.39% and a net margin of 16.50%. The firm’s quarterly revenue was up 29.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.29 earnings per share. On average, analysts anticipate that Medpace Holdings, Inc. will post 6.97 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently weighed in on MEDP shares. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Friday, October 28th. UBS Group upgraded Medpace from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $142.00 to $238.00 in a research report on Thursday, October 27th. Finally, Robert W. Baird lifted their target price on Medpace from $217.00 to $226.00 in a research report on Friday, January 13th.
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.